Several antiangiogenic agents targeting vascular endothelial growth factor (VEGF) or its receptor (VEGFR), such as bevacizumab, sorafenib, and sunitinib, have been designed and used for cancer treatment [5, 6]. The gene discussed is VEGFA; the disease is cancer.